MYLAN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN, and what generic alternatives to MYLAN drugs are available?
MYLAN has seven hundred and thirty-eight approved drugs.
There are forty-five US patents protecting MYLAN drugs. There are forty-three tentative approvals on MYLAN drugs.
There are three hundred and three patent family members on MYLAN drugs in forty-two countries and one thousand one hundred and forty-six supplementary protection certificates in eighteen countries.
Summary for MYLAN
International Patents: | 303 |
US Patents: | 45 |
Tradenames: | 515 |
Ingredients: | 465 |
NDAs: | 738 |
Patent Litigation for MYLAN: | See patent lawsuits for MYLAN |
PTAB Cases with MYLAN as petitioner: | See PTAB cases with MYLAN as petitioner |
Drugs and US Patents for MYLAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Technologies | ESTRADIOL | estradiol | SYSTEM;TRANSDERMAL | 201675-003 | Dec 19, 2014 | AB1 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Mylan Pharms Inc | EPROSARTAN MESYLATE | eprosartan mesylate | TABLET;ORAL | 202012-001 | Nov 16, 2011 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Mylan Pharms Inc | MONTELUKAST SODIUM | montelukast sodium | TABLET, CHEWABLE;ORAL | 079142-002 | Aug 3, 2012 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Mylan | ONDANSETRON | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 078139-001 | Jun 25, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MYLAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan | EXTINA | ketoconazole | AEROSOL, FOAM;TOPICAL | 021738-001 | Jun 12, 2007 | 7,553,835 | ⤷ Try a Trial |
Mylan Speciality Lp | DEMADEX | torsemide | TABLET;ORAL | 020136-004 | Aug 23, 1993 | RE30633 | ⤷ Try a Trial |
Mylan | ZOVIRAX | acyclovir | TABLET;ORAL | 020089-002 | Apr 30, 1991 | 4,199,574 | ⤷ Try a Trial |
Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-003 | Jul 12, 1996 | 5,466,700*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MYLAN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | Nasal Spray | 0.125 mg base/spray | ➤ Subscribe | 2005-11-14 |
➤ Subscribe | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL | ➤ Subscribe | 2008-11-21 |
➤ Subscribe | Inhalation Solution | 0.021% and 0.042% | ➤ Subscribe | 2005-10-19 |
➤ Subscribe | Nasal Spray | 205.5 mcg/spray | ➤ Subscribe | 2011-12-15 |
➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-04-29 |
➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | for Injection | 1 mg/vial, 2 mg/vial and 5 mg/vial | ➤ Subscribe | 2013-12-27 |
➤ Subscribe | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL | ➤ Subscribe | 2008-11-21 |
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2006-12-13 |
➤ Subscribe | Inhalation Solution | 300 mg/5 mL | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Nasal Spray | 137 mcg/50 mcg per spray | ➤ Subscribe | 2014-06-13 |
➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
➤ Subscribe | CapsulesInhalation Solution | 0.02 mg/2 mL | ➤ Subscribe | 2009-01-21 |
International Patents for MYLAN Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2578594 | ⤷ Try a Trial |
Australia | 2005258078 | ⤷ Try a Trial |
Mexico | PA05010842 | ⤷ Try a Trial |
Spain | 2814129 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MYLAN Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0193926 | C980031 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512 |
1874117 | 2014/032 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121 |
0564409 | 02C0012 | France | ⤷ Try a Trial | PRODUCT NAME: IMATINIB MESILATE; NAT. REGISTRATION NO/DATE: EU/1/01/198/001 20011107; FIRST REGISTRATION: LI - IKS 55 807 20010621 |
1381356 | 14C0010 | France | ⤷ Try a Trial | PRODUCT NAME: TERIFLUNOMIDE,SON STEREOISOMERE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES.; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.